Nontuberculous mycobacteria: Opportunistic environmental pathogens for predisposed hosts

British Medical Bulletin

Volumn 96, Issue 1, 2010, Pages 45-59

  Cook, James L ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

clinical presentation; diagnosis; environmental pathogen; epidemiology; nontuberculous mycobacteria; pulmonary disease; treatment

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOXITIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; IMIPENEM; LINEZOLID; MACROLIDE; MOXIFLOXACIN; RIFABUTIN; RIFAMPICIN; TIGECYCLINE;

ADD ON THERAPY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BRONCHIECTASIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG COST; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; GENETIC RISK; GEOGRAPHIC DISTRIBUTION; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HOST PATHOGEN INTERACTION; HUMAN; INFECTION RISK; LUNG INFECTION; MULTICENTER STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM; NEUROLOGIC DISEASE; NONHUMAN; NONTUBERCULOUS MYCOBACTERIAL INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG DISEASES; MYCOBACTERIUM INFECTIONS, ATYPICAL; OPPORTUNISTIC INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 78649685020     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldq035     Document Type: Review

References (37)

1. Falkinham JO III. Nontuberculous mycobacteria in the environment. Clin Chest Med 2002;23:529-51.
2. Pagnier I, Merchat M, Raoult D et al. Emerging Mycobacteria spp. in cooling towers. Emerg Infect Dis 2009;15:121-2.
3. Feazel LM, Baumgartner LK, Peterson KL et al. Opportunistic pathogens enriched in shower-head biofilms. Proc Natl Acad Sci USA 2009;106:16393-9.
4. Parker BC, Ford MA, Gruft H et al. Epidemiology of infection by nontuberculous mycobac-teria. IV. Preferential aerosolization of Mycobacterium intracellulare from natural waters. Am Rev Respir Dis 1983;128:652-6.
5. Wallace RJ Jr, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo- outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol 1998;52:453-90.
6. Arnow PM, Bakir M, Thompson K et al. Endemic contamination of clinical specimens by Mycobacterium gordonae. Clin Infect Dis 2000;31:472-6.
7. Prince DS, Peterson DD, Steiner RM et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989;321:863-8.
8. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease. Incidence, presentation, and response to therapy in a community setting. Am Rev Respir Dis 1991;143:1381-5.
9. Hartman TE, Swensen SJ, Williams DE. Mycobacterium avium-intracellulare complex: evaluation with CT. Radiology 1993;187:23-6.
10. Lynch DA, Simone PM, Fox MA et al. CT features of pulmonary Mycobacterium avium complex infection. J Comput Assist Tomogr 1995;19:353-60.
11. Hollings NP, Wells AU, Wilson R et al. Comparative appearances of non-tuberculous myco-bacteria species: a CT study. Eur Radiol 2002;12:2211-7.
12. Khoor A, Leslie KO, Tazelaar HD et al. Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung). Am J Clin Pathol 2001;115:755-62.
13. Aksamit TR. Hot tub lung: infection, inflammation, or both? Semin Respir Infect 2003;18:33-9.
14. Kilby JM, Gilligan PH, Yankaskas JR et al. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992;102:70-5.
15. Kim JS, Tanaka N, Newell JD et al. Nontuberculous mycobacterial infection: CT scan findings, genotype, and treatment responsiveness. Chest 2005;128:3863-9.
16. Chan ED, Kaminska AM, Gill W et al. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scand J Infect Dis 2007;39:690-6.
17. Yim JJ, Kim HJ, Kwon OJ et al. Association between microsatellite polymorphisms in intron II of the human Toll-like receptor 2 gene and nontuberculous mycobacterial lung disease in a Korean population. Hum Immunol 2008;69:572-6.
18. Koh WJ, Kwon OJ, Kim EJ et al. NRAMP1 gene polymorphism and susceptibility to nontu-berculous mycobacterial lung diseases. Chest 2005;128:94-101.
19. Tanaka G, Shojima J, Matsushita I et al. Pulmonary Mycobacterium avium complex infection: association with NRAMP1 polymorphisms. Eur Respir J 2007;30:90-6.
20. Shojima J, Tanaka G, Keicho N et al. Identification of MICA as a susceptibility gene for pulmonary Mycobacterium avium complex infection. J Infect Dis 2009;199:1707-15.
21. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
22. Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003;37:1178-82.
23. Whittier S, Hopfer RL, Knowles MR et al. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 1993;31:861-4.
24. Davidson PT, Khanijo V, Goble M et al. Treatment of disease due to Mycobacterium intracel-lulare. Rev Infect Dis 1981;3:1052-9.
25. Heifets LB. Synergistic effect of rifampin, streptomycin, ethionamide, and ethambutol on Mycobacterium intracellulare. Am Rev Respir Dis 1982;125:43-8.
26. Yajko DM, Kirihara J, Sanders C et al. Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother 1988;32:1392-5.
27. Hoffner SE, Kratz M, Olsson-Liljequist B et al. In-vitro synergistic activity between ethambu-tol and fluorinated quinolones against Mycobacterium avium complex. J Antimicrob Chemother 1989;24:317-24.
28. Hjelm U, Kaustova J, Kubin M et al. Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid. Eur J Clin Microbiol Infect Dis 1992;11:51-4.
29. Hoffner SE, Hjelm U, Kallenius G. Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. Antimicrob Agents Chemother 1993;37:1285-8.
30. Griffith DE, Brown BA, Cegielski P et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000;30:288-92.
31. Al-Abdely HM, ReVankar SG, Graybill JR. Disseminated Mycobacterium simiae infection in patients with AIDS. J Infect 2000;41:143-7.
32. Valero G, Moreno F, Graybill JR. Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection. Antimicrob Agents Chemother 1994;38:2676-7.
33. Conde MB, Efron A, Loredo C et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;373:1183-9.
34. Wallace RJ Jr, Brown-Elliott BA, Ward SC et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001;45:764-7.
35. Wallace RJ Jr, Brown-Elliott BA, Crist CJ et al. Comparison of the in vitro activity of the gly-cylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxy-cycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002;46:3164-7.
36. Fernandez-Roblas R, Martin-de-Hijas NZ, Fernandez-Martinez AI et al. In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. Antimicrob Agents Chemother 2008;52:4184-6.
37. Peloquin CA. Mycobacterium avium complex infection. Pharmacokinetic and pharmacody-namic considerations that may improve clinical outcomes. Clin Pharmacokinet 1997;32:132-44.